Pasithea Therapeutics financials
$0.4900+2.08%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$5.7M | -$4.9M | -$10.3M | -$3.1M | -$3.8M | -$3.7M | -$3.3M | -$3.0M | -$3.9M | -$4.0M | -$5.1M | -$3.8M |
| Net income | -$5.3M | -$2.9M | -$10.1M | -$3.0M | -$3.7M | -$3.6M | -$3.2M | -$3.0M | -$3.9M | -$3.9M | -$5.0M | -$3.6M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.16 | $-0.12 | $-0.79 | $-0.41 | $-0.66 | $-1.61 | $-2.53 | $-2.87 | $-3.71 | $-3.70 | $-4.86 | $-2.87 |
| EBITDA | -$5.9M | -$4.7M | -$10.1M | -$2.9M | -$4.0M | -$3.5M | -$3.1M | -$2.8M | -$3.8M | -$3.9M | -$5.0M | -$3.6M |
| Operating cash flow | -$4.7M | -$4.8M | -$5.4M | -$2.9M | -$3.9M | -$3.1M | -$2.4M | -$3.1M | -$4.0M | -$4.3M | -$3.3M | -$3.2M |
| Free cash flow | -$4.7M | -$4.8M | -$5.4M | -$2.9M | -$3.9M | -$3.1M | -$2.4M | -$3.1M | -$4.0M | -$4.3M | -$3.3M | -$3.3M |
| Diluted shares | 32.1M | 24.3M | 12.8M | 7.4M | 5.6M | 2.2M | 1.3M | 1.0M | 1.0M | 1.0M | 1.0M | 1.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $45.7M | $50.4M | $55.2M | $4.1M | $7.2M | $5.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $51.7M | $56.4M | $60.2M | $13.6M | $17.0M | $14.7M |
| Total liabilities | $1.9M | $1.5M | $5.0M | $1.4M | $1.8M | $1.7M |
| Shareholders' equity | $49.8M | $54.8M | $55.2M | $12.2M | $15.2M | $13.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology